- Home
- ATCH vs ATOS Comparison
ATCH vs ATOS Comparison
Compare ATCH & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCH | ATOS |
|---|---|---|
| Founded | 2022 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 24.1M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ATCH | ATOS |
|---|---|---|
| Price | $0.19 | $2.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.0M | 53.9K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $84.47 | N/A |
| Revenue Next Year | $39.32 | N/A |
| P/E Ratio | $3.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.53 |
| 52 Week High | $1.92 | $7.56 |
Technical Indicators
Market Signals| Indicator | ATCH | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 47.08 |
| Support Level | $0.19 | $2.05 |
| Resistance Level | $0.22 | $2.60 |
| Average True Range (ATR) | 0.01 | 0.18 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 13.00 | 24.97 |
Price Performance
Historical ComparisonAbout ATCH AtlasClear Holdings Inc.
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.